Abstract
Intravenously infused L-dopa (0.3 mg/kg per min) produced hypertension and cardiac arrhythmias in halothane anesthetized dogs. Biochemical studies showed that the heart, kidney, and brain of these animals accumulated significant amounts of catecholamines formed from the administered precursor.
Pretreatment of dogs with an extracerebral inhibitor of dopa decarboxylase [D,L-α-hydrazino-α-methyl-β-(3.4-dihydroxyphenyl) propionic acid] prevented the development of hypertension and arrhythmias with infusion of L-dopa. Instead, these animals developed significant hypotension. The heart and kidney of these animals accumulated markedly reduced amounts of catecholamines formed from L-dopa compared with dogs receiving L-dopa alone: the amount of catecholamines accumulated in brain was unchanged. L-dopa, after extracerebral decarboxylase inhibition, appeared to produce hypotension by reducing peripheral vascular resistance without altering sympathetic nerve function. During hypotension, cardiac output was not altered and arterial pressure in perfused hindlimbs fell, even though flow was maintained. The pressor response to intravenous injections of norepinephrine and dopamine was unchanged. Hindlimb arterial pressure response to direct electrical stimulation of the lumbar sympathetic trunk was also unchanged.
Pretreatment with a drug which inhibits brain as well as extracerebral dopa decarboxylase [D,L-seryl-2,3,4-trihydroxybenzylhydrazine hydrochloride] abolished all effects of L-dopa on blood pressure. In these animals, there was a marked reduction of catecholamine formation from L-dopa in the brain as well as the heart and kidney.
It appears that L-dopa produces opposite effects on blood pressure depending on the site of accumulation of its metabolic products, dopamine and norepinephrine. If L-dopa is rapidly decarboxylated to catecholamines in peripheral organs, hypertension and cardiac arrhythmias occur. If peripheral dopa decarboxylase is selectively inhibited, a centrally mediated hypotensive effect, probably secondary to the accumulation of catecholamines in the brain, becomes apparent. If dopa decarboxylase is inhibited in the brain in addition to extracerebral organs, L-dopa has no effect on blood pressure.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bartholini G., Pletscher A. Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine. J Pharm Pharmacol. 1969 May;21(5):323–324. doi: 10.1111/j.2042-7158.1969.tb08258.x. [DOI] [PubMed] [Google Scholar]
- Calne D. B., Brennan J., Spiers A. S., Stern G. M. Hypotension caused by L-dopa. Br Med J. 1970 Feb 21;1(5694):474–475. doi: 10.1136/bmj.1.5694.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Constantinidis J., Bartholini G., Tissot R., Pletscher A. Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain. Experientia. 1968 Feb 15;24(2):130–131. doi: 10.1007/BF02146939. [DOI] [PubMed] [Google Scholar]
- Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
- EBLE J. N. A PROPOSED MECHANISM FOR THE DEPRESSOR EFFECT OF DOPAMINE IN THE ANESTHETIZED DOG. J Pharmacol Exp Ther. 1964 Jul;145:64–70. [PubMed] [Google Scholar]
- Henning M., Rubenson A. Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat. J Pharm Pharmacol. 1970 Aug;22(8):553–560. doi: 10.1111/j.2042-7158.1970.tb10570.x. [DOI] [PubMed] [Google Scholar]
- Katz R. L., Katz G. J. Surgical infiltration of pressor drugs and their interaction with volatile anaesthetics. Br J Anaesth. 1966 Sep;38(9):712–718. doi: 10.1093/bja/38.9.712. [DOI] [PubMed] [Google Scholar]
- Lotti V. J., Porter C. C. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors. J Pharmacol Exp Ther. 1970 Apr;172(2):406–415. [PubMed] [Google Scholar]
- McDowell F., Lee J. E., Swift T., Sweet R. D., Ogsbury J. S., Kessler J. T. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa). Ann Intern Med. 1970 Jan;72(1):29–35. doi: 10.7326/0003-4819-72-1-29. [DOI] [PubMed] [Google Scholar]
- Musacchio J. M., Fischer J. E., Kopin I. J. Subcellular distribution and release by sympathetic nerve stimulation of dopamine and alpha-methyl dopamine. J Pharmacol Exp Ther. 1966 Apr;152(1):51–55. [PubMed] [Google Scholar]
- PROCHNIK G., MAISON G. L., STUTZMAN J. W. Carotid-occlusion-pressor reflex: influence of existing mean arterial pressure, of anesthetics and of ganglionic- and adrenergic-blocking drugs. Am J Physiol. 1950 Sep;162(3):553–559. doi: 10.1152/ajplegacy.1950.162.3.553. [DOI] [PubMed] [Google Scholar]
- Watanabe A. M., Chase T. N., Cardon P. V. Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther. 1970 Sep-Oct;11(5):740–746. doi: 10.1002/cpt1970115740. [DOI] [PubMed] [Google Scholar]
- Whitsett T. L., Halushka P. V., Goldberg L. I. Attenuation of postganglionic sympathetic nerve activity by L-dopa. Circ Res. 1970 Oct;27(4):561–570. doi: 10.1161/01.res.27.4.561. [DOI] [PubMed] [Google Scholar]
- Yahr M. D., Duvoisin R. C., Schear M. J., Barrett R. E., Hoehn M. M. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343–354. doi: 10.1001/archneur.1969.00480160015001. [DOI] [PubMed] [Google Scholar]
- Yamori Y., Lovenberg W., Sjoerdama A. Norepinephrine metabolism in brainstem of spontaneously hypertensive rats. Science. 1970 Oct 30;170(3957):544–546. doi: 10.1126/science.170.3957.544. [DOI] [PubMed] [Google Scholar]